Experimental combo shows promise in Tough-to-Treat melanoma
NCT ID NCT01659151
First seen Nov 06, 2025 · Last updated Apr 25, 2026 · Updated 16 times
Summary
This study tested a combination of a targeted drug (vemurafenib), special immune cells (T-cells), and high-dose IL-2 in 17 people with advanced melanoma that had spread. The goal was to see if this approach could shrink or control tumors. While the treatment aims to fight the cancer, it does not offer a cure, and ongoing management is typically needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.